What exactly changed in the ORIC analyst rating on Feb 24, 2026?

H.C. Wainwright maintained a **Buy** and raised the ORIC price target to **$25** from **$23** on February 24, 2026. The ORIC analyst rating reflects continued confidence in clinical progress while acknowledging company financing activity.

How should investors interpret the ORIC analyst rating and $25 target?

The ORIC analyst rating signals expected upside tied to pipeline milestones. The **$25** target is an analyst estimate, not a promise. Investors should compare the target to market cap, dilution risk, and their time horizon before acting.

Does the ORIC analyst rating consider recent financing activity?

Yes. The note comes as ORIC filed a new **$200 million** at-the-market program and previously raised about **$139.7 million** gross. The ORIC analyst rating balances funding needs against long-term clinical potential.

How reliable is one analyst’s ORIC analyst rating for investment decisions?

A single ORIC analyst rating provides a credible viewpoint but not a consensus. Limited coverage increases influence of each note. Use the rating alongside financials, filings, and Meyka AI’s grade to form a fuller view.

Analyst Ratings

H.C. Wainwright Maintains Buy on ORIC (ORIC Pharmaceuticals, Inc.) Feb 2026

ByDanny Kontos February 25, 2026February 25, 2026

On February 24, 2026 H.C. Wainwright maintained a Buy on ORIC (ORIC Pharmaceuticals, Inc.) and raised its price target to $25 from $23. The ORIC analyst rating update signals continued confidence in ORIC’s oncology pipeline despite recent financing activity. Investors should note the firm increased the target and kept the positive stance on the stock.